214 related articles for article (PubMed ID: 26577210)
1. Parotid Sebaceous Carcinoma in Patient with Muir Torre Syndrome, Caused by MSH2 Mutation.
Neelakantan IV; Di Palma S; Smith CE; McCoombe A
Head Neck Pathol; 2016 Sep; 10(3):354-61. PubMed ID: 26577210
[TBL] [Abstract][Full Text] [Related]
2. Muir-Torre Syndrome and founder mismatch repair gene mutations: A long gone historical genetic challenge.
Ponti G; Manfredini M; Tomasi A; Pellacani G
Gene; 2016 Sep; 589(2):127-32. PubMed ID: 26143115
[TBL] [Abstract][Full Text] [Related]
3. Synchronous gastric and sebaceous cancers, a rare manifestation of MLH1-related Muir-Torre syndrome.
Svec J; Schwarzová L; Janošíková B; Stekrová J; Mandys V; Kment M; Vodička P
Int J Clin Exp Pathol; 2014; 7(8):5196-202. PubMed ID: 25197397
[TBL] [Abstract][Full Text] [Related]
4. Fordyce granules and hyperplastic mucosal sebaceous glands as distinctive stigmata in Muir-Torre syndrome patients: characterization with reflectance confocal microscopy.
Ponti G; Meschieri A; Pollio A; Ruini C; Manfredini M; Longo C; Mandel VD; Ciardo S; Tomasi A; Giannetti L; Pellacani G
J Oral Pathol Med; 2015 Aug; 44(7):552-7. PubMed ID: 25213213
[TBL] [Abstract][Full Text] [Related]
5. [Muir-Torre syndrome and Turcot syndrome].
Velter C; Caussade P; Fricker JP; Cribier B
Ann Dermatol Venereol; 2017; 144(8-9):525-529. PubMed ID: 28256262
[TBL] [Abstract][Full Text] [Related]
6. Muir-Torre syndrome: sebaceous carcinoma concurrent with colon cancer in a kidney transplant recipient; a case report.
Tomonari M; Shimada M; Nakada Y; Yamamoto I; Itoh M; Koike Y; Kobayashi A; Miki J; Yamada H; Kimura T; Saito S; Sugano K; Sekine S; Yamamoto H; Asahina A; Yokoo T
BMC Nephrol; 2019 Oct; 20(1):394. PubMed ID: 31664942
[TBL] [Abstract][Full Text] [Related]
7. Muir-Torre Syndrome with Novel Mutation in the MSH2 Gene.
Ustaoglu E; Agirgol S; Aymelek HS; Turhan EI
Acta Dermatovenerol Croat; 2023 Dec; 31(3):144-147. PubMed ID: 38439724
[TBL] [Abstract][Full Text] [Related]
8. Clinical and Molecular Features of Skin Malignancies in Muir-Torre Syndrome.
Simic D; Dummer R; Freiberger SN; Ramelyte E; Barysch MJ
Genes (Basel); 2021 May; 12(5):. PubMed ID: 34065301
[TBL] [Abstract][Full Text] [Related]
9. Germline Testing of Mismatch Repair Genes Is Needed in the Initial Evaluation of Patients With Muir-Torre Syndrome-Associated Cutaneous Sebaceous Neoplasms: A Case Series.
Cohen PR; Kurzrock R
Cureus; 2023 Jan; 15(1):e33975. PubMed ID: 36824550
[TBL] [Abstract][Full Text] [Related]
10. Sebaceous Neoplasms.
Flux K
Surg Pathol Clin; 2017 Jun; 10(2):367-382. PubMed ID: 28477886
[TBL] [Abstract][Full Text] [Related]
11. Value of MLH1 and MSH2 mutations in the appearance of Muir-Torre syndrome phenotype in HNPCC patients presenting sebaceous gland tumors or keratoacanthomas.
Ponti G; Losi L; Pedroni M; Lucci-Cordisco E; Di Gregorio C; Pellacani G; Seidenari S
J Invest Dermatol; 2006 Oct; 126(10):2302-7. PubMed ID: 16826164
[TBL] [Abstract][Full Text] [Related]
12. Analysis of Sebaceous Neoplasms for DNA Mismatch Repair Proteins in Muir-Torre Syndrome.
Pollinger TH; Kieliszak CR; Logemann N; Gratrix ML
Skinmed; 2017; 15(4):259-264. PubMed ID: 28859734
[TBL] [Abstract][Full Text] [Related]
13. Muir-Torre Syndrome in a Middle-Aged Chinese Patient with Sebaceous Carcinoma of the Eyelid.
Wong CY; Tang RK; Lam RF; Io IY; Yuen CY; Ho JW; Tse RK
Semin Ophthalmol; 2015; 30(5-6):420-2. PubMed ID: 24117411
[TBL] [Abstract][Full Text] [Related]
14. Patients with a new-onset cutaneous sebaceous neoplasm following immunosuppression should be evaluated for Muir-Torre syndrome with germline mismatch repair gene mutation analysis: case reports.
Cohen PR; Kurzrock R
Dermatol Online J; 2024 Mar; 30(1):. PubMed ID: 38762859
[TBL] [Abstract][Full Text] [Related]
15. Retroperitoneal undifferentiated pleomorphic sarcoma having microsatellite instability associated with Muir-Torre syndrome: case report and review of literature.
Lee N; Luthra R; Lopez-Terrada D; Wang WL; Lazar AJ
J Cutan Pathol; 2013 Aug; 40(8):730-3. PubMed ID: 23672746
[TBL] [Abstract][Full Text] [Related]
16. A clinical scoring system to identify patients with sebaceous neoplasms at risk for the Muir-Torre variant of Lynch syndrome.
Roberts ME; Riegert-Johnson DL; Thomas BC; Rumilla KM; Thomas CS; Heckman MG; Purcell JU; Hanson NB; Leppig KA; Lim J; Cappel MA
Genet Med; 2014 Sep; 16(9):711-6. PubMed ID: 24603434
[TBL] [Abstract][Full Text] [Related]
17. Loss of DNA mismatch repair proteins in skin tumors from patients with Muir-Torre syndrome and MSH2 or MLH1 germline mutations: establishment of immunohistochemical analysis as a screening test.
Mathiak M; Rütten A; Mangold E; Fischer HP; Ruzicka T; Friedl W; Propping P; Kruse R
Am J Surg Pathol; 2002 Mar; 26(3):338-43. PubMed ID: 11859205
[TBL] [Abstract][Full Text] [Related]
18. Muir-Torre syndrome.
Bhaijee F; Brown AS
Arch Pathol Lab Med; 2014 Dec; 138(12):1685-9. PubMed ID: 25427047
[TBL] [Abstract][Full Text] [Related]
19. Muir-Torre syndrome and recent updates on screening guidelines: The link between colorectal tumors and sebaceous adenomas in unusual locations.
Shaker N; Shaker N; Abid A; Shah S; Shakra RA; Sangueza OP
J Surg Oncol; 2023 Dec; 128(8):1380-1384. PubMed ID: 37706607
[TBL] [Abstract][Full Text] [Related]
20. [Muir-Torre syndrome--a phenotypic variant of Lynch syndrome].
Kacerovská D; Kazakov DV; Cerná K; Hadravský L; Michal M; Dostál J; Skálová A; Michal M
Cesk Patol; 2010 Oct; 46(4):86-94. PubMed ID: 21313735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
